EGFR and non-small cell lung carcinoma: Zorifertinib (AZD3759), a novel EGFR‐TKI inhibiting mutant EGFR (exon 19del or L858R), is not a substrate of either P‐glycoprotein or breast cancer resistance protein and was designed specifically to improve blood–brain barrier (BBB) penetration10, 11 and to treat EGFR‐mutant NSCLC patients with BM.